NASDAQ:SNGXSoligenix Stock Price, Forecast & News

$2.12

+0.07 (+3.41 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.04

Now: $2.12▼

$2.19

50-Day Range

$1.41

MA: $1.67▼

$2.10

52-Week Range

$0.67

Now: $2.12▼

$3.54

Volume699,358 shs

Average Volume831,270 shs

Market Capitalization$56.34 million

P/E RatioN/A

Dividend YieldN/A

Beta1.17

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Soligenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Soligenix has a potential upside of 88.7% from its current price of $2.12.
Amount of Analyst Coverage
Soligenix has only been the subject of 1 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Soligenix has received 271 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Soligenix has received 201 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Soligenix has received 57.42% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote “Outperform” if you believe SNGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Soligenix does not currently pay a dividend.
Dividend Growth
Soligenix does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Soligenix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 16.03% of the stock of Soligenix is held by insiders.
Percentage Held by Institutions
Only 10.51% of the stock of Soligenix is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Soligenix are expected to grow in the coming year, from ($0.49) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Soligenix is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Soligenix is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Soligenix has a P/B Ratio of 30.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SNGX

Previous Symbol

CUSIPN/A

CIK812796

Webwww.soligenix.com

Phone609-538-8200

Debt

Debt-to-Equity RatioN/A

Current Ratio1.51

Quick Ratio1.51

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.60 million

Price / Sales12.25

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.07 per share

Price / Book30.29

Profitability

EPS (Most Recent Fiscal Year)($0.48)

Net Income$-9,360,000.00

Net Margins-351.69%

Return on Equity-542.83%

Return on Assets-174.30%

Miscellaneous

Employees14

Outstanding Shares26,577,000

Market Cap$56.34 million

Next Earnings Date8/11/2020 (Estimated)

OptionableNot Optionable

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

How has Soligenix's stock been impacted by COVID-19 (Coronavirus)?

Soligenix's stock was trading at $2.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SNGX shares have decreased by 16.5% and is now trading at $2.12. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Soligenix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soligenix.

When is Soligenix's next earnings date?

Soligenix is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Soligenix.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its quarterly earnings results on Friday, May, 15th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.21. The biopharmaceutical company had revenue of $0.90 million for the quarter. Soligenix had a negative return on equity of 542.83% and a negative net margin of 351.69%. View Soligenix's earnings history.

What price target have analysts set for SNGX?

1 analysts have issued 1 year price targets for Soligenix's stock. Their forecasts range from $4.00 to $4.00. On average, they expect Soligenix's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price. View analysts' price targets for Soligenix.

Has Soligenix been receiving favorable news coverage?

Media coverage about SNGX stock has been trending negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Soligenix earned a news impact score of -2.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutSoligenix.

Who are some of Soligenix's key competitors?

Some companies that are related to Soligenix include LifeVantage (LFVN), Inflarx (IFRX), Gemphire Therapeutics (GEMP), Kalvista Pharmaceuticals (KALV), Paratek Pharmaceuticals (PRTK), Lexicon Pharmaceuticals (LXRX), NuCana (NCNA), IVERIC bio (ISEE), Chimerix (CMRX), Aravive (ARAV), vTv Therapeutics (VTVT), Nature's Sunshine Products (NATR), Aduro BioTech (ADRO), Kindred Biosciences (KIN) and Tyme Technologies (TYME). View all competitors.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Trevena (TRVN), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), ImmunoGen (IMGN), Nokia Oyj (NOK) and Verastem (VSTM).

Who are Soligenix's key executives?

Soligenix's management team includes the following people:

Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 53)
Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 65)
Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 47)
Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 67)
Mr. Richard L. Dunning, Exec. Officer (Age 73)

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by many different retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (0.43%), First Wilshire Securities Management Inc. (0.39%), S&T Bank PA (0.15%), WMS Partners LLC (0.10%) and Savant Capital LLC (0.06%). Company insiders that own Soligenix stock include Christopher J Schaber, Diane L Parks, Jerome B Zeldis and Mark E Pearson. View institutional ownership trends for Soligenix.

Which major investors are buying Soligenix stock?

SNGX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, First Wilshire Securities Management Inc., S&T Bank PA, WMS Partners LLC, and Savant Capital LLC. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Diane L Parks, Jerome B Zeldis, and Mark E Pearson. View insider buying and selling activity for Soligenix.

How do I buy shares of Soligenix?

Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $2.12.

How big of a company is Soligenix?

Soligenix has a market capitalization of $56.34 million and generates $4.60 million in revenue each year. The biopharmaceutical company earns $-9,360,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. Soligenix employs 14 workers across the globe.

What is Soligenix's official website?

The official website for Soligenix is www.soligenix.com.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff